2022-10-21

ROI-NJ: BD’s new Onclarity HPV test greatly improves standard of care for women

ROI-NJ: BD’s new Onclarity HPV test greatly improves standard of care for women

Molly Broache, Associate Director, Medical Affairs for US IDS explains how the BD Onclarity™ HPV Assay positively impacts public health by providing a more precise estimate of a woman’s risk of cervical precancer and cancer.

Latest resources

Discover our latest articles, webinars, press releases and updates in women's health.

BD blog: The future of cervical cancer screening: More genotypes means more precise care
Cervical Cancer | News & Updates
BD blog: The future of cervical cancer screening: More genotypes means more precise care
Doctor giving patient brochure
Cervical Cancer | News & Updates
Press Release: New Survey Finds Women Are Skipping Their OB/GYN Exams, Increasing Risks for Cervical Cancer
Chris Beddard, Vice President, U.S. Marketing, Integrated Diagnostic Solutions at BD
Cervical Cancer | News & Updates
NJBIZ Conversations: Chris Beddard